Iovance Biotherapeutics (NASDAQ:IOVA) received a $13.00 price objective from equities research analysts at Oppenheimer in a report released on Thursday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would suggest a potential upside of 59.51% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, September 1st. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, August 31st. Jefferies Group restated a “buy” rating and set a $11.00 price objective on shares of Iovance Biotherapeutics in a research note on Tuesday, September 5th. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Finally, B. Riley raised their price objective on shares of Iovance Biotherapeutics from $17.50 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 1st. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $14.53.

Shares of Iovance Biotherapeutics (NASDAQ:IOVA) traded down $0.55 during trading on Thursday, hitting $8.15. 537,122 shares of the company traded hands, compared to its average volume of 371,777. Iovance Biotherapeutics has a 52 week low of $4.45 and a 52 week high of $9.50.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). analysts anticipate that Iovance Biotherapeutics will post -1.37 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. 683 Capital Management LLC bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $2,325,000. Perceptive Advisors LLC grew its stake in shares of Iovance Biotherapeutics by 8.3% in the third quarter. Perceptive Advisors LLC now owns 4,726,114 shares of the biotechnology company’s stock worth $36,627,000 after acquiring an additional 363,000 shares during the period. Orbimed Advisors LLC grew its stake in shares of Iovance Biotherapeutics by 89.9% in the third quarter. Orbimed Advisors LLC now owns 6,425,626 shares of the biotechnology company’s stock worth $49,799,000 after acquiring an additional 3,042,726 shares during the period. Jane Street Group LLC bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $164,000. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Iovance Biotherapeutics by 6.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 222,015 shares of the biotechnology company’s stock worth $1,721,000 after acquiring an additional 12,883 shares during the period. Institutional investors and hedge funds own 75.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/14/iovance-biotherapeutics-iova-pt-set-at-13-00-by-oppenheimer.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.